CVM
Price
$9.40
Change
-$3.64 (-27.91%)
Updated
Aug 28, 04:30 PM (EDT)
Capitalization
89.74M
MDGL
Price
$435.00
Change
+$9.94 (+2.34%)
Updated
Aug 28, 04:06 PM (EDT)
Capitalization
9.47B
63 days until earnings call
Interact to see
Advertisement

CVM vs MDGL

Header iconCVM vs MDGL Comparison
Open Charts CVM vs MDGLBanner chart's image
Cel-Sci
Price$9.40
Change-$3.64 (-27.91%)
Volume$200
Capitalization89.74M
Madrigal Pharmaceuticals
Price$435.00
Change+$9.94 (+2.34%)
Volume$200
Capitalization9.47B
CVM vs MDGL Comparison Chart in %
Loading...
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CVM vs. MDGL commentary
Aug 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVM is a Buy and MDGL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 28, 2025
Stock price -- (CVM: $13.04 vs. MDGL: $425.06)
Brand notoriety: CVM: Notable vs. MDGL: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CVM: 56% vs. MDGL: 103%
Market capitalization -- CVM: $89.74M vs. MDGL: $9.47B
CVM [@Biotechnology] is valued at $89.74M. MDGL’s [@Biotechnology] market capitalization is $9.47B. The market cap for tickers in the [@Biotechnology] industry ranges from $99.27B to $0. The average market capitalization across the [@Biotechnology] industry is $1.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CVM’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • CVM’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, both CVM and MDGL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CVM’s TA Score shows that 4 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • CVM’s TA Score: 4 bullish, 4 bearish.
  • MDGL’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than CVM.

Price Growth

CVM (@Biotechnology) experienced а +46.52% price change this week, while MDGL (@Biotechnology) price change was +8.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.20%. For the same industry, the average monthly price growth was +14.79%, and the average quarterly price growth was +30.49%.

Reported Earning Dates

MDGL is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($9.47B) has a higher market cap than CVM($89.7M). MDGL YTD gains are higher at: 37.752 vs. CVM (8.694). CVM has higher annual earnings (EBITDA): -20.81M vs. MDGL (-266.74M). MDGL has more cash in the bank: 797M vs. CVM (1.79M). CVM has less debt than MDGL: CVM (9.96M) vs MDGL (124M). MDGL has higher revenues than CVM: MDGL (516M) vs CVM (0).
CVMMDGLCVM / MDGL
Capitalization89.7M9.47B1%
EBITDA-20.81M-266.74M8%
Gain YTD8.69437.75223%
P/E RatioN/AN/A-
Revenue0516M-
Total Cash1.79M797M0%
Total Debt9.96M124M8%
FUNDAMENTALS RATINGS
CVM vs MDGL: Fundamental Ratings
CVM
MDGL
OUTLOOK RATING
1..100
1727
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
67
Overvalued
PROFIT vs RISK RATING
1..100
10027
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3537
P/E GROWTH RATING
1..100
50100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (67) in the Pharmaceuticals Other industry is somewhat better than the same rating for CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew somewhat faster than CVM’s over the last 12 months.

MDGL's Profit vs Risk Rating (27) in the Pharmaceuticals Other industry is significantly better than the same rating for CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew significantly faster than CVM’s over the last 12 months.

MDGL's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as CVM (100) in the Biotechnology industry. This means that MDGL’s stock grew similarly to CVM’s over the last 12 months.

CVM's Price Growth Rating (35) in the Biotechnology industry is in the same range as MDGL (37) in the Pharmaceuticals Other industry. This means that CVM’s stock grew similarly to MDGL’s over the last 12 months.

CVM's P/E Growth Rating (50) in the Biotechnology industry is somewhat better than the same rating for MDGL (100) in the Pharmaceuticals Other industry. This means that CVM’s stock grew somewhat faster than MDGL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CVMMDGL
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 14 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CVM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RLBFX37.690.07
+0.19%
American Funds American Balanced R5
FCVCX16.92N/A
N/A
Fidelity Advisor Small Cap Value C
TCMIX18.77N/A
N/A
AMG TimesSquare International SmallCap Z
NNLEX25.60N/A
N/A
Nicholas Limited Edition N
APHTX25.57-0.01
-0.04%
Artisan Focus Fund Institutional

MDGL and

Correlation & Price change

A.I.dvisor indicates that over the last year, MDGL has been loosely correlated with ALXO. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDGL jumps, then ALXO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MDGL
1D Price
Change %
MDGL100%
+0.05%
ALXO - MDGL
56%
Loosely correlated
+9.09%
NAGE - MDGL
45%
Loosely correlated
-2.74%
IPHA - MDGL
44%
Loosely correlated
N/A
RNAC - MDGL
43%
Loosely correlated
-1.44%
GHRS - MDGL
43%
Loosely correlated
+1.79%
More